Display options
Cite
Chang AY, Ying XX. Brain Metastases from Breast Cancer and Response to Treatment with Eribulin: A Case Series. Breast Cancer (Auckl). 2015;9:19-24doi: 10.4137/BCBCR.S21176.
Chang, A. Y., & Ying, X. X. (2015). Brain Metastases from Breast Cancer and Response to Treatment with Eribulin: A Case Series. Breast cancer : basic and clinical research, 919-24. https://doi.org/10.4137/BCBCR.S21176
Chang, Alex Y, and Ying, Xu Xiao. "Brain Metastases from Breast Cancer and Response to Treatment with Eribulin: A Case Series." Breast cancer : basic and clinical research vol. 9 (2015): 19-24. doi: https://doi.org/10.4137/BCBCR.S21176
Chang AY, Ying XX. Brain Metastases from Breast Cancer and Response to Treatment with Eribulin: A Case Series. Breast Cancer (Auckl). 2015 May 24;9:19-24. doi: 10.4137/BCBCR.S21176. eCollection 2015. PMID: 26052228; PMCID: PMC4444132.
Copy Download .nbib Format: NLM
Share it on

Breast Cancer (Auckl). 2015 May 24;9:19-24. doi: 10.4137/BCBCR.S21176. eCollection 2015.

Brain Metastases from Breast Cancer and Response to Treatment with Eribulin: A Case Series.

Breast cancer : basic and clinical research

Alex Y Chang, Xu Xiao Ying

Affiliations

  1. Department of Medical Oncology, Johns Hopkins Singapore International Medical Centre, Johns Hopkins University, Singapore. ; Research Department, Johns Hopkins Singapore Pte Ltd, Singapore.
  2. Research Department, Johns Hopkins Singapore Pte Ltd, Singapore.

PMID: 26052228 PMCID: PMC4444132 DOI: 10.4137/BCBCR.S21176

Abstract

Brain metastases are common in patients with advanced breast cancer (BC), causing considerable morbidity and mortality. Eribulin is a microtubule dynamics inhibitor approved for treating certain patients with metastatic BC, previously treated with an anthracycline and a taxane. In the 301 phase 3 study in 1102 women with advanced BC, eribulin and capecitabine treatments did not differ for co-primary endpoints (overall survival [OS]: 15.9 vs 14.5 months, P = 0.056; progression-free survival [PFS]: 4.1 vs 4.2 months, P = 0.30). Here, we report outcomes for six patients (eribulin, n = 3; capecitabine, n = 3) who had received treatment for brain metastases from BC (BCBM) at baseline. All eribulin-treated patients experienced brain lesion shrinkage at some point during treatment, compared with one capecitabine-treated patient. Fewer patients in study 301 developed new BCBM with eribulin (13/544, 2.4%) compared with capecitabine (25/546, 4.6%). Eribulin does not cross the healthy blood-brain barrier (BBB), but could have the potential to do so after cranial radiation therapy. Capecitabine may cross the BBB and has demonstrated activity in BCBM. Data from these patients and previous cases suggest that further investigation of eribulin for BCBM may be warranted.

Keywords: advanced breast cancer; brain metastases; capecitabine; case series; eribulin

References

  1. Xenobiotica. 2011 Apr;41(4):320-6 - PubMed
  2. Oncol Rep. 2002 Jul-Aug;9(4):683-8 - PubMed
  3. J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 - PubMed
  4. Mol Cancer Ther. 2008 Jul;7(7):2003-11 - PubMed
  5. Clin Cancer Res. 2009 Feb 15;15(4):1452-9 - PubMed
  6. Lancet. 2011 Mar 12;377(9769):914-23 - PubMed
  7. Cancer Invest. 2006 Jun-Jul;24(4):466-8 - PubMed
  8. Int J Radiat Oncol Biol Phys. 1990 Dec;19(6):1507-10 - PubMed
  9. BMC Res Notes. 2013 Dec 18;6:541 - PubMed
  10. Cancer Res. 2009 Jun 15;69(12):4951-3 - PubMed
  11. Clin Cancer Res. 2007 Mar 15;13(6):1648-55 - PubMed
  12. Case Rep Oncol Med. 2012;2012:537183 - PubMed
  13. Breast Cancer Res Treat. 2014 Dec;148(3):553-61 - PubMed
  14. Clin Exp Metastasis. 2013 Dec;30(8):951-6 - PubMed
  15. Oncologist. 2013 Jun;18(6):675-84 - PubMed
  16. Neuro Oncol. 2015 Feb;17(2):289-95 - PubMed
  17. Br J Cancer. 2007 Aug 6;97(3):322-6 - PubMed
  18. Oncologist. 2001;6(1):56-64 - PubMed
  19. J Neurooncol. 2007 Nov;85(2):223-7 - PubMed
  20. Clin Breast Cancer. 2006 Jun;7(2):164-6 - PubMed
  21. J Clin Oncol. 2009 Jun 20;27(18):2954-61 - PubMed
  22. Biochemistry. 2010 Feb 16;49(6):1331-7 - PubMed
  23. Bioorg Med Chem Lett. 2011 Mar 15;21(6):1639-43 - PubMed
  24. Lancet Oncol. 2013 Jan;14(1):64-71 - PubMed
  25. J Clin Oncol. 2015 Feb 20;33(6):594-601 - PubMed
  26. Bioorg Med Chem Lett. 2012 Dec 15;22(24):7363-6 - PubMed
  27. Am J Clin Oncol. 2001 Aug;24(4):421-4 - PubMed
  28. J Clin Oncol. 2010 Sep 1;28(25):3922-8 - PubMed
  29. Cancer. 2006 Sep 15;107(6):1348-54 - PubMed

Publication Types